IQVIA Holdings Valuation

Is I1QV34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of I1QV34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: I1QV34 (R$300.4) is trading below our estimate of fair value (R$387.18)

Significantly Below Fair Value: I1QV34 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for I1QV34?

Key metric: As I1QV34 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for I1QV34. This is calculated by dividing I1QV34's market cap by their current earnings.
What is I1QV34's PE Ratio?
PE Ratio	26x
Earnings	US$1.41b
Market Cap	US$36.56b

I1QV34 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	17.3x
PEG Ratio	1.9x

Price to Earnings Ratio vs Peers

How does I1QV34's PE Ratio compare to its peers?

The above table shows the PE ratio for I1QV34 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	44x
A Agilent Technologies	30.6x	8.2%	US$39.4b
LONN Lonza Group	65.6x	23.8%	CHF 37.6b
MTD Mettler-Toledo International	33x	7.6%	US$26.2b
WST West Pharmaceutical Services	46.9x	12.9%	US$23.4b
I1QV34 IQVIA Holdings	26x	13.9%	R$36.6b

Price-To-Earnings vs Peers: I1QV34 is good value based on its Price-To-Earnings Ratio (26x) compared to the peer average (43.9x).

Price to Earnings Ratio vs Industry

How does I1QV34's PE Ratio compare vs other companies in the Global Life Sciences Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: I1QV34 is good value based on its Price-To-Earnings Ratio (26x) compared to the Global Life Sciences industry average (35.8x).

Price to Earnings Ratio vs Fair Ratio

What is I1QV34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

I1QV34 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	26x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate I1QV34's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Gilead Sciences

US$115.2b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD34

US$272.97

5.4%

48.5%

Novartis

CHF 186.7b

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

N1VS34

CHF 62.27

3.0%

29.7%

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

B1GN34

US$49.40

8.9%

n/a